| 1 (130) | Hypertension Arterielle, Pulmonaire: Physiopathologie et Innovation Therapeutique | FRA |  |
| 2 (144) | GlaxoSmithKline, United Kingdom | GBR | |
| 3 (150) | Hoffmann-La Roche Ltd, United States | USA | |
| 4 (154) | Genentech Inc | USA | |
| 5 (179) | Boehringer Ingelheim GmbH Germany | DEU | |
| 6 (235) | AstraZeneca, United States | USA | |
| 7 (260) | Boehringer Ingelheim, USA | USA | |
| 8 (264) | Merck & Co Inc, United States | USA | |
| 9 (288) | GlaxoSmithKline, United States | USA | |
| 10 (291) | AstraZeneca, Sweden | SWE | |
| 11 (346) | AstraZeneca, United Kingdom | GBR | |
| 12 (547) | Novartis Pharmaceuticals, United States | USA | |
| 13 (580) | Novartis, Switzerland | CHE | |
| 14 (625) | Regeneron Pharmaceuticals Inc | USA | |
|
